Factors associated with neurocognitive test performance at baseline: a substudy of the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial.

Wright, E J; Grund, B; Cysique, L A; Robertson, K R; Brew, B J; Collins, G; Shlay, J C; Winston, A; Read, T R H; Price, R W

Wright, E J; Grund, B; Cysique, L A; Robertson, K R; Brew, B J; Collins, G; Shlay, J C; Winston, A; Read, T R H; Price, R W.

Affiliation

Wright EJ; Department of Infectious Diseases, Alfred Hospital and Monash University, Melbourne, Victoria, Australia; Burnet Institute, Melbourne, Victoria, Australia.

HIV Med ; 16 Suppl 1: 97-108, 2015 Apr.

Article in En | MEDLINE | ID: mdl-25711328

Subject(s)

Cognition Disorders/epidemiology; HIV Infections/complications; Adolescent; Adult; Argentina; Brazil; CD4 Lymphocyte Count; Chile; Female; HIV Infections/immunology; Humans; Male; Middle Aged; Neuropsychological Tests; Prevalence; Young Adult

Key words

HIV; HIV-associated neurocognitive disorders; antiretroviral therapy naïve; neurocognitive performance

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Health context: 2_ODS3 Database: MEDLINE Main subject: HIV Infections / Cognition Disorders Type of study: Clinical_trials / Prevalence_studies / Risk_factors_studies Limits: Adolescent / Adult / Female / Humans / Male / Middle aged Country/Region as subject: America do sul / Argentina / Brasil / Chile Language: En Journal: HIV Med Year: 2015 Document type: Article

Fulltext

XML

PubMed Links

Search on Google